LWLina Wu

Lina Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lina Wu has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Xilin Sun

    Department of Nuclear Medicine, Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China; NHC Key Laboratory of Molecular Probe and Targeted Diagnosis and Therapy, Molecular Imaging Research Center (MIRC) of Harbin Medical University, Harbin 150028, China

    5 shared publications
  • Kai Wang

    H MRI. Moreover, AH111972-PFCE NPs could be ultralong retained in metastatic liver tumors for at least 7 days, which is conductive to the implementation of continuous therapeutic efficacy monitoring. The NPs with minimal side effects and good biocompatibility are cleared mainly via the spleen and liver

    4 shared publications
  • Lili Yang

    H MRI. Moreover, AH111972-PFCE NPs could be ultralong retained in metastatic liver tumors for at least 7 days, which is conductive to the implementation of continuous therapeutic efficacy monitoring. The NPs with minimal side effects and good biocompatibility are cleared mainly via the spleen and liver

    4 shared publications
  • Hongyan Zou

    H MRI. Moreover, AH111972-PFCE NPs could be ultralong retained in metastatic liver tumors for at least 7 days, which is conductive to the implementation of continuous therapeutic efficacy monitoring. The NPs with minimal side effects and good biocompatibility are cleared mainly via the spleen and liver

    3 shared publications
  • Yingbo Li

    H MRI. Moreover, AH111972-PFCE NPs could be ultralong retained in metastatic liver tumors for at least 7 days, which is conductive to the implementation of continuous therapeutic efficacy monitoring. The NPs with minimal side effects and good biocompatibility are cleared mainly via the spleen and liver

    3 shared publications
  • Daoshuang Li

    H MRI. Moreover, AH111972-PFCE NPs could be ultralong retained in metastatic liver tumors for at least 7 days, which is conductive to the implementation of continuous therapeutic efficacy monitoring. The NPs with minimal side effects and good biocompatibility are cleared mainly via the spleen and liver

    2 shared publications

Latest Publications

  • Open Access

    Chitosan-Coated Pirfenidone/Azithromycin Coloaded Liposomal Inhalation Platform for Synergistic Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

    by Kaiqi Wang, Sijie Cheng, Chenyang Zhao, Xueqi Zhao, Zheng Lv, Lina Wu

    Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), frequently triggered by infections, is characterized by acute inflammation occurring on top of progressive fibrosis, resulting in high mortality rates and a lack of effective treatments. This study aimed to disrupt the “infection–inflammation–fibrosis” cascade through a chitosan-coated liposomal formulation that co-loads pirfenidone (PFD) and azithromycin (AZM) for nebulized inhalation (CS-PFD/AZM-Lip). Methods: The formulation utilized a dipalmitoylphosphatidylcholine (DPPC)/cholesterol lipid backbone that closely resembles the endogenous pulmonary surfactant. The liposomal surface was electrostatically coated with chitosan to enhance mucoadhesion, antibacterial synergy, and aerosolization stability. We characterized particle size, polydispersity index (PDI), zeta potential, and encapsulation efficiency, alongside stability assessments during nebulization and storage at 4 °C. In vitro release was evaluated in bronchoalveolar lavage fluid from bleomycin/lipopolysaccharide-challenged mice, simulating the pathological microenvironment. Cellular uptake and antifibrotic effects were examined in TGF-β1-activated fibroblasts, while efficacy and safety were tested in a bleomycin- and lipopolysaccharide-induced AE-IPF mouse model. Results: CS-PFD/AZM-Lip demonstrated a uniform size of 138.83 ± 0.31 nm (PDI 0.251 ± 0.009), a zeta potential of +23.67 ± 1.27 mV, and encapsulation efficiencies of 83.7% (PFD) and 86.0% (AZM), all of which remained unchanged following nebulization, with an 8-week stability at 4 °C. Both drugs exhibited enhanced release in the simulated pathological microenvironment. The formulation was efficiently internalized by activated fibroblasts, significantly suppressing migration, myofibroblast differentiation, and collagen production at both transcriptional and protein levels. In AE-IPF mice, nebulized CS-PFD/AZM-Lip attenuated pulmonary inflammation and collagen deposition compared to oral free drugs, improved lung function and survival, and showed no detectable toxicity in major organs or in hematological, serum biochemical, and hemolysis assessments. Conclusions: This study successfully synthesized the CS-PFD/AZM-Lip nano-liposome for nebulized inhalation. By integrating clinically established therapeutic regimens with an inhalable nanocarrier platform, CS-PFD/AZM-Lip presents a highly promising novel strategy for the treatment of AE-IPF.

  • Synchronizing Tumor Oxygen Dynamics via 19F-MRI-Guided Nanotheranostics Enables Precision Radiotherapy

    by ChunPing Hu, Shuang Liu, Yongchen Zhang, Xueqi Zhao, Kaiqi Wang, Wenjuan Zhao, Fangyu Zhao, Jiaqi Yang, Tianchi Yan, Panpan Wang, et al.

    The therapeutic efficacy of radiotherapy (RT) is fundamentally constrained by tumor hypoxia, a dynamic and heterogeneous feature of the tumor microenvironment that drives radioresistance and disease progression. Despite advances in oxygen-supplementation strategies, the inability to resolve and exploit temporal oxygen fluctuations limits their clinical impact. Here, we report a fluorine-19 MRI-guided nanotheranostic platform that synchronizes tumor oxygen dynamics with precision radiotherapy. Perfluorocarbon-based nanodroplets function dually as oxygen carriers and quantitative imaging probes, leveraging the linear dependence of the 19F longitudinal relaxation rate (R1) on the oxygen partial pressure (pO2) to enable noninvasive mapping of tumor oxygenation. This approach identifies a transient peak oxygenation window following administration, providing a rational basis for temporally optimized RT delivery. Synchronizing irradiation with this imaging-defined window significantly amplifies reactive oxygen species (ROS) generation and DNA double-strand breaks, resulting in enhanced tumor regression and prolonged survival. Beyond direct radiosensitization, this strategy establishes a paradigm for converting stochastic hypoxia into a controllable therapeutic variable. This work presents a framework for timing-informed, image-guided precision radiotherapy, advancing the frontier of oxygen-modulated cancer therapy.

  • Open Access

    Controlled Release of Hydrogen‐Carrying Perfluorocarbons for Ischemia Myocardium‐Targeting 19F MRI‐Guided Reperfusion Injury Therapy

    by Chaoqun Nie, Rong A, Jing Wang, Shuang Pan, Rentong Zou, Bin Wang, Shuiqing Xi, Xiaojian Hong, Meifang Zhou, Haoyu Wang, et al.

    Hydrogen gas is recently proven to have anti‐oxidative and anti‐inflammation effects on ischemia‐reperfusion injury. However, the efficacy of hydrogen therapy is limited by the efficiency of hydrogen storage, targeted delivery, and controlled release. In this study, H2‐PFOB nanoemulsions (NEs) is developed with high hydrogen loading capacity for targeted ischemic myocardium precision therapy. The hydrogen‐carrying capacity of H2‐PFOB NEs is determined by gas chromatography and microelectrode methods. Positive uptake of H2‐PFOB NEs in ischemia‐reperfusion myocardium and the influence of hydrogen on 19F‐MR signal are quantitatively visualized using a 9.4T MR imaging system. The biological therapeutic effects of H2‐PFOB NEs are examined on a myocardial ischemia‐reperfusion injury mouse model. The results illustrated that the developed H2‐PFOB NEs can efficaciously achieve specific infiltration into ischemic myocardium and exhibit excellent antioxidant and anti‐inflammatory properties on myocardial ischemia‐reperfusion injury, which can be dynamically visualized by 19F‐MR imaging system. Moreover, hydrogen burst release induced by low‐intensity focused ultrasound (LIFU) irradiation further promotes the therapeutic effect of H2‐PFOB NEs with a favorable biosafety profile. In this study, the potential therapeutic effects of H2‐PFOB NEs is fully unfolded, which may hold great potential for future hydrogen‐based precision therapeutic applications tailored to ischemia‐reperfusion injury.


  • Open Access

    c-Met-Targeting 19F MRI Nanoparticles with Ultralong Tumor Retention for Precisely Detecting Small or Ill-Defined Colorectal Liver Metastases

    by Daoshuang Li, Jie Yang, Zuoyu Xu, Yingbo Li, Yige Sun, Yuchen Wang, Hongyan Zou, Kai Wang, Lili Yang, Lina Wu, et al.

    Purpose: Precisely detecting colorectal liver metastases (CLMs), the leading cause of colorectal cancer-associated mortality, is extremely important. 1H MRI with high soft tissue resolution plays a key role in the diagnosing liver lesions; however, precise detecting CLMs by 1H MRI is a great challenge due to the limited sensitivity. Even though contrast agents may improve the sensitivity, due to their short half-life, repeated injections are required to monitor the changes of CLMs. Herein, we synthesized c-Met-targeting peptide-functionalized perfluoro-15-crown-5-ether nanoparticles (AH111972-PFCE NPs), for highly sensitive and early diagnosis of small CLMs. Methods: The size, morphology and optimal properties of the AH111972-PFCE NPs were characterized. c-Met specificity of the AH111972-PFCE NPs was validated by in vitro experiment and in vivo 19F MRI study in the subcutaneous tumor murine model. The molecular imaging practicability and long tumor retention of the AH111972-PFCE NPs were evaluated in the liver metastases mouse model. The biocompatibility of the AH111972-PFCE NPs was assessed by toxicity study. Results: AH111972-PFCE NPs with regular shape have particle size of 89.3 ± 17.8 nm. The AH111972-PFCE NPs exhibit high specificity, strong c-Met-targeting ability, and precise detection capability of CLMs, especially small or ill-defined fused metastases in 1H MRI. Moreover, AH111972-PFCE NPs could be ultralong retained in metastatic liver tumors for at least 7 days, which is conductive to the implementation of continuous therapeutic efficacy monitoring. The NPs with minimal side effects and good biocompatibility are cleared mainly via the spleen and liver. Conclusion: The c-Met targeting and ultralong tumor retention of AH111972-PFCE NPs will contribute to increasing therapeutic agent accumulation in metastatic sites, laying a foundation for CLMs diagnosis and further c-Met targeted treatment integration. This work provides a promising nanoplatform for the future clinical application to patients with CLMs.


  • Alveolar Macrophages-Mediated Translocation of Intratracheally Delivered Perfluorocarbon Nanoparticles to Achieve Lung Cancer 19F-MR Imaging

    by Hongbin Wang, Xiaona Li, Jing Wang, Jiannan Wang, Hongyan Zou, Xuesong Hu, Linqing Yang, Penghui Shen, Rong A, Kaiqi Wang, et al.

    Recent advances in intratracheal delivery strategies have sparked considerable biomedical interest in developing this promising approach for lung cancer diagnosis and treatment. However, there are very few relevant studies on the behavior and mechanism of imaging nanoparticles (NPs) after intratracheal delivery. Here, we found that nanosized perfluoro-15-crown-5-ether (PFCE NPs, ∼200 nm) exhibite significant 19F-MRI signal-to-noise ratio (SNR) enhancement than perfluorooctyl bromide (PFOB NPs) up to day 7 after intratracheal delivery. Alveolar macrophages (AMs) engulf PFCE NPs, become PFCE NPs-laden AMs, and then migrate into the tumor margin, resulting in increased tumor PFCE concentration and 19F-MRI signals. AMs-mediated translocation of PFCE NPs to lung draning lymph nodes (dLNs) decreases the background PFCE concentration. Our results shed light on the dynamic AMs-mediated translocation of intratracheally delivered PFC NPs for effective lung tumor visualization and reveal a pathway to develop and promote the clinical translation of an intratracheal delivery-based imaging strategy.


  • Open Access

    Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC

    by Yige Sun, Jie Yang, Yingbo Li, Jing Luo, Jiemei Sun, Daoshuang Li, Yuchen Wang, Kai Wang, Lili Yang, Lina Wu, et al.

    Background: Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (INC280) hold promise for clinically NSCLC treatment. However, the major obstacles of MET-targeted therapy are poor drug solubility and off-tumor effects, even oral high-dosing regimens cannot significantly increase the therapeutic drug concentration in primary and metastatic NSCLC. Methods: We developed a multirooted delivery system INC280-PFCE nanoparticles (NPs) by loading INC280 into perfluoro-15-crown-5-ether for improving MET-targeted therapy. Biodistribution and anti-MET/antimetastatic effects of NPs were validated in orthotopic NSCLC and NSCLC liver metastasis models in a single low-dose. The efficacy of INC280-PFCE NPs was also explored in human NSCLC specimens. Results: INC280-PFCE NPs exhibited excellent antitumor ability in vitro. In orthotopic NSCLC models, sustained release and prolonged retention behaviors of INC280-PFCE NPs within tumors could be visualized in real-time by 19F magnetic resonance imaging (19F-MRI), and single pulmonary administration of NPs showed more significant tumor growth inhibition than oral administration of free INC280 at a tenfold higher dose. Furthermore, a single low-dose INC280-PFCE NPs administered intravenously suppressed widespread dissemination of liver metastasis without systemic toxicity. Finally, we verified the clinical translation potential of INC280-PFCE NPs in human NSCLC specimens. Conclusions: These results demonstrated high anti-MET/antimetastatic efficacies, real-time MRI visualization and high biocompatibility of NPs after a single low-dose.


  • Open Access

    New Studies of the Aberrant Alterations in Fibrillin-1 Methylation During Colorectal Cancer Development

    by Ling Lv, Jianzhong Ma, Lina Wu, Chao Zhang, Yueping Wang, Guang Wang

    Background: Fibrillin-1 (FBN1) methylation risk from control to colorectal cancer (CRC), the variation regularities of FBN1 methylation, and DNA methyltransferase (DNMT) catalyzed with FBN1 methylation had not been reported yet; these were all studied in this paper. Methods: FBN1 methylation roles were investigated with big data and meta-analysis. Results: The 6 independent studies were searched including 702 tissue and 448 feces. FBN1 methylation frequencies of CRC, adenoma or polyp, and control in tissue were 79.1%, 69.4%, and 2.7%, respectively; those in feces were 74.6%, 50.7%, and 10.8%, respectively. FBN1 methylation of control samples was used as a standard reference; this study showed that ORs (95% CI) of FBN1 methylation in CRC and control tissues were 124.79 (62.86–248.35); those in feces were detected to be 30.87 (16.48–57.85). FBN1 methylation risk in tissue was higher than that in feces; there was a quadratic equation between the methylation rate of tissue and that of feces. There was another quadratic curve in the variation process of FBN1 methylation; this curve reflected the overall metabolism regularity of DNMT. Conclusions: The transcriptional inactivation of FBN1 gene might start from normal colonic epithelium; the quadratic curve of FBN1 methylation catalyzed by DNMT can gradually produce powerful strength, accelerate expansion, and eventually lead to CRC. The overall metabolism regularity of DNMT maintains the changing process of FBN1 methylation; it has the changing feature of the same quadratic curve. FBN1 methylation is a promising biomarker. FBN1 methylation risk size in feces reflects that in tissue in non-invasive detection.


  • Update on the development of molecular imaging and nanomedicine in China: Optical imaging

    by Lina Wu, Hongyan Zou, Hongbin Wang, Sihang Zhang, Shuang Liu, Ying Jiang, Jing Chen, Yingbo Li, Mengping Shao, Ruixin Zhang, et al.

    Molecular imaging has received increased attention worldwide, including in China, because it offers noninvasive characterization of widely diverse clinically significant pathologies. To achieve these goals, nanomedicine has evolved into a broad interdisciplinary field with flexible designs to accommodate and concentrate imaging and therapeutic payloads into pathological cells through selective binding to disease specific cell membrane biomarkers. This concept of personalized medicine reflects the vision of “magic bullets” proposed by German biochemist Paul Ehrlich over 100 years ago. As happening worldwide, Chinese scientists are contributing to this tsunami of science and technologies through impactful national programs and international research collaborations. This review provides a comprehensive update of Chinese innovations to address intractable unmet medical need in China and worldwide in the optical sciences.This article is categorized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging


  • Highly Selective Electrocatalytic Reduction of CO2 into Methane on Cu–Bi Nanoalloys

    by Zhijiang Wang, Qi Yuan, Jingjing Shan, Zhaohua Jiang, Ping Xu, Yongfeng Hu, Jigang Zhou, Lina Wu, Zhuangzhuang Niu, Jianmin Sun, et al.

    Methane (CH4), the main component of natural gas, is one of the most valuable products facilitating energy storage via electricity conversion. However, the poor selectivity and high overpotential for CH4 formation with metallic Cu catalysts prevent realistic applications. Introducing a second element to tune the electronic state of Cu has been widely used as an effective method to improve catalytic performance, but achieving high selectivity and activity toward CH4 remains challenging. Here, we successfully synthesized Cu–Bi NPs, which exhibit a CH4 Faradaic efficiency (FE) of as high as 70.6% at −1.2 V vs reversible hydrogen electrode (RHE). The FE of Cu–Bi NPs has increased by approximately 25-fold compared with that of Cu NPs. DFT calculations showed that alloying Cu with Bi significantly decreases the formation energy of *COH formation, the rate-determining step, which explains the improved performance. Further analysis showed that Cu that has been partially oxidized due to electron withdrawal by Bi is the most possible active site.